C4 Therapeutics, Inc.
CCCCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Valued at $462.6M, CCCC is a small-cap name in its sector. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Market Cap
$462.6M
Beta
2.94
P/E (TTM)
—
P/E (Fwd)
-3.77
EPS (TTM)
$-0.91
EPS (Fwd)
$-1.00
ROE
-48.1%
ROA
-19.3%
Cash
$253.7M
Total Debt
$56.9M
Free CF
-$43.7M
52W Change
40.3%
Annual Financials
Cash vs Debt
Where CCCC stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CCCC finished 18.35% above its 150-day moving average ($3.27) and 27.72% above its 200-day moving average ($3.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CCCC overbought or oversold?
At the September 2, 2026 close, CCCC's RSI(14) was 49.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $253.7M in cash comfortably exceeding the $56.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$43.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $31.1M to $35.9M.
C4 Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for C4 Therapeutics, Inc. and its sector.